IL6 and glioma: Recent work supports the role of IL-6 in malignant progression of gliomas: of 146 differentially expressed genes, using TCGA-LGG data, only IL-6 emerged as an immune-related biomarker, and a therapeutic target, with a negative association between IL-6 and overall survival; low levels of IL-6 correlated with IDH1 mutation, a positive prognostic marker [Yang et al., 2024].